Clinical Trials
95 trials[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer
Aalborg University Hospital
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
AbbVie
Topical Curcumin for HPV Related Cervical Disease
Emory University
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
Shandong Cancer Hospital and Institute
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Corcept Therapeutics
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
ART-Hypo
Centre hospitalier de l'Université de Montréal (CHUM)
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
The Methodist Hospital Research Institute
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Psyence Australia Pty Ltd
Charlie-2
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
PICCOLO
AbbVie
Potlako+
Brigham and Women's Hospital
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Aadi Bioscience, Inc.
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
AbbVie
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
OC-POP-PT
Tel-Aviv Sourasky Medical Center
Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer
Shandong Cancer Hospital and Institute
SOCCER-P
Korea University Guro Hospital
HPV-VIM
Baylor College of Medicine
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Exelixis
MiMe-A
Jules Bordet Institute
Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions
Catalysis SL
Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer
Loyola University
NEOPRIMA
The University of Hong Kong
A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation
Sumitomo Pharma America, Inc.
ALpha-T
Hoffmann-La Roche
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sheba Medical Center
COPELIA
University of Manchester
Intraoperative Pathological Evaluation for Surgical Treatment & Staging for Endometrial Cancer
University of Kentucky
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
PharmaMar
TIVO
Northwestern University
TOPIC
Vall d'Hebron Institute of Oncology
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer
Nektar Therapeutics
TRACEII
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
CINOVA
Cristal Therapeutics
Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer
Eli Lilly and Company
AVANIRA3
Jiangsu Cancer Institute & Hospital
ANLOLA
Jiangsu Cancer Institute & Hospital
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
Quest PharmaTech Inc.
Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
Lumos Pharma
CRC-PIPAC
Catharina Ziekenhuis Eindhoven
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
Eli Lilly and Company
V3-OVA
Immunitor LLC
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Masonic Cancer Center, University of Minnesota
SIGNATURE
Novartis
Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers
Belgian Gynaecological Oncology Group
METRO-BIBF
University College, London
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
Incyte Corporation
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
Pfizer